Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022

Effectiveness against severe COVID-19 of a second booster dose of the bivalent (original/BA.4–5) mRNA vaccine 7–90 days post-administration, relative to a first booster dose of an mRNA vaccine received ≥ 120 days earlier, was ca 60% both in persons ≥ 60 years never infected and in those infected > 6 months before. Relative effectiveness in those infected 4–6 months earlier indicated no significant additional protection (10%; 95% CI:−44 to 44). A second booster vaccination 6 months after the latest infection may be warranted.

Source: Eurosurveillance - February 23, 2023 Category: Infectious Diseases Authors: Massimo Fabiani, Alberto Mateo-Urdiales, Chiara Sacco, Emmanouil Alexandros Fotakis, Maria Cristina Rota, Daniele Petrone, Marco Bressi, Martina Del Manso, Andrea Siddu, Giorgio Fedele, Paola Stefanelli, Antonino Bella, Flavia Riccardo, Anna Teresa Palama Source Type: research